ONCOSIMIS BIOTECH
  • Home
  • About Us
  • Technologies
  • OnCovid™
  • Pipeline
  • Funding & Awards
  • Contact Us
  • More
    • Home
    • About Us
    • Technologies
    • OnCovid™
    • Pipeline
    • Funding & Awards
    • Contact Us

ONCOSIMIS BIOTECH

  • Home
  • About Us
  • Technologies
  • OnCovid™
  • Pipeline
  • Funding & Awards
  • Contact Us
image631

OnCovid™

A Rapid, sensitive & high-throughput screening method for detection of SARS-CoV-2 antibodies or antigen using Bio-Layer Interferometry (BLI) technology.

Find out more

OnCovid™ Ab/Ag Detection

Brief about OnCovid™

Present pandemic scenario, there exists an unmet global need for the development of a rapid and sensitive method for the detection of SARS-CoV-2 infection. The available options for identification of SARS-CoV-2 infection are detection of viral RNA by qRT-PCR, Antigen or Antibody testing by serological methods. Even though many kits available commercially but none of them are rapid, sensitive and high throughput. ‘OnCovid antibody and antigen assay’ is a diagnostic method developed by us uses the principle of bio layer Interferometry (BLI) to detect IgM, IgA and IgG antibodies against SARS-CoV-2 and detect antigen as Spike protein of SARS-CoV-2 virus. This method overcomes many of the limitations normally faced in antibody detection by other methods and offers a superior platform for a rapid, sensitive and specific detection of SARS-CoV-2 infection. The test is economical, and the results can be obtained >10 seconds per test. In addition to its standalone use in early diagnosis of SARS-CoV-2, ‘OnCovid™ total antibody’ can be used to therapeutic monitoring of antiviral therapies used in clinical management and to estimate the antibody titers during convalescent plasma donation. 


Advantages of OnCovid™ antibody/antigen assay: 

> It offers rapid and High Throughput detection of total antibodies with real-time data monitoring.

> A 384 Well plate data can be acquired and analysed within 30 min.

> It does not need 'storage related' changes as the complete assay is done on a real time.

> OnCovid™ method does not need additional steps such as washing, incubation, substrate addition etc...

> It offers high throughput can measure one complete 384 Plate at a time providing a sample throughput of 10,000 samples within 12 Hours.

> It needs less technician intervention due to higher Automation and provides better clinically significant data.

> Cost Effective, Higher Throughput and more condent data.

> This is label free platform provides information on the accurate quantities of antibodies with appropriate standards**. 

OnCovid™

OnCovid™ total antibody/antigen assay has very high sensitivity and specificity for detecting antibodies against COVID-19 and antigen (Spike protein) compared to the existing technologies as this approach uses a pool of recombinant protein and mAbs to capture anti-2019-nCoV IgM/A/G in plasma during and after SARS CoV-2 infection or a antigen (Spike protein) in saliva or swabs. 

Find out more

Copyright © 2018 Oncosimis® Biotech Pvt Ltd - All Rights Reserved.

Powered by GoDaddy